- Medical news & Guidelines
- Cardiology and CTVS
- Critical Care
- Diabetes and Endocrinology
- Laboratory Medicine
- Health news
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Dadra and Nagar Haveli
- Daman and Diu
- Himachal Pradesh
- Jammu & Kashmir
- Madhya Pradesh
- Tamil Nadu
- Uttar Pradesh
- West Bengal
- Medical Education
Conduct Active Surveillance Study: CDSCO Panel tells Cipla on Idiopathic Pulmonary Fibrosis Drug Pirfenidone tablet
New Delhi: Denying the pharma major Cipla's request for waiver of an active surveillance study, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has suggested the firm conduct an active surveillance study for Pirfenidone 200 mg tablets, which is a novel antifibrotic oral agent used for the treatment of idiopathic pulmonary...
New Delhi: Denying the pharma major Cipla's request for waiver of an active surveillance study, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has suggested the firm conduct an active surveillance study for Pirfenidone 200 mg tablets, which is a novel antifibrotic oral agent used for the treatment of idiopathic pulmonary fibrosis.
This came after the firm presented their proposal for a request for waiver of an active surveillance study before the committee.
Pirfenidone is an agent used for the treatment of idiopathic pulmonary fibrosis (IPF). It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia.
IPF is a rare and progressive respiratory disorder marked by the thickness and stiffening of lung tissue as well as the production of scar tissue. It's a form of chronic scarring lung disease that causes a steady reduction in lung function that's irreversible. Shortness of breath and a dry cough are two of the most common symptoms. Other symptoms include fatigue and unusually large, dome-shaped fingers and toenails. Pulmonary hypertension, heart failure, pneumonia, and pulmonary embolism are all possible complications.
Pirfenidone's exact mode of action and specific molecular targets are still unknown. The chemical, on the other hand, possesses anti-fibrotic, anti-inflammatory, and antioxidant properties. Suppression of TGF-1 (transforming growth factor-1), a major cytokine involved in fibrogenesis and extracellular matrix synthesis, is one key anti-fibrotic approach.
Pirfenidone 200 mg is available in India under the brands Pirfemac 200mg Tablet 10s from Macleods, Pirfenex 200 Mg Tablet 15s from Cipla, and Fibrodone 200mg Tablet 10s from Lupin.
Earlier, the Medical Dialogues Team had reported that Cipla had gotten approval from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to conduct the single-dose and multiple-dose bioequivalence study (BE study) of Pirfenidone Extended Release Tablets 1200 mg.
In continuation, at the most recent SEC meeting for pulmonary, held on September 29, 2022, the committee thoroughly examined the drug-maker Cipla's proposal for a waiver of the active surveillance study of Pirfenidone 200 mg tablets.
After detailed deliberation, the committee reiterated its earlier recommendation and suggested that the firm needs to conduct an active surveillance study.
In accordance with the above, the committee directed the firm to submit a protocol for further review.
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.